Domestic pharmaceutical companies are attacking innovative drugs, but these problems remain to be solved

Recently, Pien Tze Huang announced that the marketing authorization holder of desloratadine oral solution was changed from Shandong Bainuo Pharmaceutical to Zhangzhou Pien Tze Huang Pharmaceutical, and the drug also became another of its innovative chemical products
.
It is understood that in recent years, Pien Tze Huang has been aggressively attacking innovative drugs.
In the first half of 2021, 11 new drug projects under research have been promoted, of which 3 chemical drug category 1 innovative drugs and 3 new traditional Chinese medicine drugs have entered the clinic
.
Domestic pharmaceutical companies are attacking innovative drugs, but these problems are still to be solved (Photo source: Pharmaceutical Network) Industry analysts believe that, in fact, from Pien Tze Huang's attack on innovative drugs, it can be clearly seen that in the field of medicine, innovation has become one of the core competitiveness
.
In addition to Pien Tze Huang, many pharmaceutical companies have been increasing investment in the research and development of innovative drugs in recent years.
At present, some companies have begun to usher in the harvest period
.
According to data, from 2016 to 2021, under the background of accelerated innovation of pharmaceutical companies, 66 domestically produced Class 1 new drugs have been launched in China; %
.
In the context of the continuous listing of innovative drugs, many pharmaceutical companies have also ushered in new growth in performance
.
For example, as of the first half of 2021, the sales revenue of Hengrui Medicine's innovative drugs has accounted for about 40% of the total revenue, which has become the company's new growth engine
.
It is worth mentioning that in the last month, Hengrui Medicine's innovative research and development achievements have followed one after another, and a total of four innovative drugs have been listed and declared for listing
.
The industry believes that as pharmaceutical companies such as Hengrui Medicine continue to accelerate the R&D and commercialization of innovative drugs that are highly anticipated, the performance of a large number of companies in the field of innovative drugs will continue to grow
.
However, in the context of the rapid development of domestic innovative drugs, it should be noted that the industry is actually facing a series of challenges
.
Among them, the trend of innovation homogenization has begun to emerge in recent years
.
It is understood that although the achievements of innovative drugs have begun to emerge, 41% of the new drugs focus on the top 6% of the hot targets in terms of targets involved in new drugs in recent years
.
As a result, the industry predicts that as pharmaceutical companies continue to increase investment in research and development, some tracks will become more crowded, and competition for many products will become more intense.

.
In this context, the author believes that pharmaceutical companies need to realize the clinical value of product differentiation as much as possible, strive to realize the value of innovative drugs in the international market, improve enterprise management capabilities, and formulate scientific sales model selection and commercialization promotion strategies , in order to better avoid homogenization and achieve higher quality development
.
In addition to homogenization, the entire innovative drug industry is currently facing a series of challenges in terms of production, commercialization, and marketing
.
In fact, the approval of a new drug is only a basic step, and subsequent related companies still need to face challenges in production, commercialization, and marketing
.
For example, in the production stage, the investment of corresponding equipment and the support of experienced talents are needed to ensure the stable operation of production; for example, in the commercialization stage, how to quickly open the product to the market will also be a problem that enterprises need to think about
.
Among them, the production link is particularly important
.
The production of innovative drugs is inseparable from the corresponding equipment support; at the same time, the degree of intelligence, digitization, automation and informationization of traditional Chinese medicine equipment is closely related to the efficiency and quality of traditional Chinese medicine extraction
.
Therefore, the industry generally believes that behind the "blowout" growth in the number of innovative Chinese medicine drugs, the field of traditional Chinese medicine pharmaceutical equipment will play a vital role
.
In this context, it is suggested in the industry to focus on the traditional Chinese medicine pharmaceutical equipment industry in the traditional Chinese medicine innovative drug industry chain
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.